We aimed to compare health-related quality of life (HRQoL) between treatment groups in this trial. Methods: CheckMate 025 was an open-label study done at 146 oncology centres in 24 countries.
Book Title: Quality of Life in Patients with Advanced Renal Cell Carcinoma Given Nivolumab Versus Everolimus in CheckMate 025: a Randomised, Open-label, Phase 3 Trial
Author:
Published on 2016 by
ISBN: /
Total Page:
Book Category:
Book is About: Carcinoma
Download Quality of Life in Patients with Advanced Renal Cell Carcinoma Given Nivolumab Versus Everolimus in CheckMate 025: a Randomised, Open-label, Phase 3 Trial eBook
Background: In the phase 3 CheckMate 025 study, previously treated patients with advanced renal cell carcinoma who were randomly assigned to nivolumab had an overall survival benefit compared with those assigned to everolimus. We aimed to compare health-related quality of life (HRQoL) between treatment groups in this trial. Methods: CheckMate 025 was an open-label study done at 146 oncology centres in 24 countries. Patients were randomly assigned to treatment between Oct 22, 2012, and March 11, 2014. Patients with advanced renal cell carcinoma were randomly assigned (1:1, block size of four) to receive nivolumab every 2 weeks or everolimus once per day. The study was stopped early at the planned interim analysis in July, 2015, because the study met its primary endpoint. A protocol amendment permitted patients in the everolimus group to cross over to nivolumab treatment. All patients not on active study therapy are being followed up for survival. At the interim analysis, HRQoL was assessed with the Functional Assessment of Cancer Therapy-Kidney Symptom Index-Disease Related Symptoms (FKSI-DRS) and European Quality of Life (EuroQol)-5 Dimensions (EQ-5D) questionnaires. Prespecified endpoints were to assess, in each treatment group, disease-related symptom progression rate based on the FKSI-DRS and changes in reported global health outcomes based on the EQ-5D. Other endpoints were post hoc. We calculated the proportion of FKSI-DRS questionnaires completed using the number of patients with non-missing data at baseline and at least one post-baseline visit. We defined FKSI-DRS completion as completion of five or more of the nine items in the questionnaire; otherwise data were treated as missing. FKSI-DRS symptom index score was prorated for missing items. We made no adjustments for missing EQ-5D data. We used descriptive statistics and multivariate analyses, including mixed-effects model repeated-measures, for between group comparisons. Analyses were powered according to the original study protocol, and we analysed FKSI-DRS and EQ-5D data for all patients who underwent randomisation and had a baseline assessment and at least one post-baseline assessment. CheckMate 025 is registered withClinicalTrials.gov, numberNCT01668784 . Findings: HRQoL data were collected at baseline for 362 (88%) of 410 patients in the nivolumab group and 344 (84%) of 411 patients in the everolimus group. The mean difference in FKSI-DRS scores between the nivolumab and everolimus groups was 1·6 (95% CI 1·4–1·9; p
Our website offers free Carcinoma Ebooks to download. Quality of Life in Patients with Advanced Renal Cell Carcinoma Given Nivolumab Versus Everolimus in CheckMate 025: a Randomised, Open-label, Phase 3 Trial is the one of great book to have from us, a free ebooks portal, the best free ebooks download library. You can find and download free ebooks in categories. No registration is required to download free e-books. We have huge collection of Carcinoma and ebooks. Each downloadable ebook has a short review with a description. You can find over thousand of ebooks that are free to download. Get ton of books with us, the open directory for free ebooks and download links, the best place to read ebooks and search free download ebooks.Carcinoma ebooks free
download Quality of Life in Patients with Advanced Renal Cell Carcinoma Given Nivolumab Versus Everolimus in CheckMate 025: a Randomised, Open-label, Phase 3 Trial ebook as PDF, EPUB, MOBI, AZW and AZW3, FB2, DJVU, LIT, RFT, IBA, LRS, LRF, and LRX.
download ebooks
There are so many ebooks about Quality of Life in Patients with Advanced Renal Cell Carcinoma Given Nivolumab Versus Everolimus in CheckMate 025: a Randomised, Open-label, Phase 3 Trial that are available to have. Thinking of having Quality of Life in Patients with Advanced Renal Cell Carcinoma Given Nivolumab Versus Everolimus in CheckMate 025: a Randomised, Open-label, Phase 3 Trial ebook? You are in the right place. Get the ebook Quality of Life in Patients with Advanced Renal Cell Carcinoma Given Nivolumab Versus Everolimus in CheckMate 025: a Randomised, Open-label, Phase 3 Trial by: .
Book Details:
- Book was ranked at 2 by Google Books for Quality of Life in Patients with Advanced Renal Cell Carcinoma Given Nivolumab Versus Everolimus in CheckMate 025: a Randomised, Open-label, Phase 3 Trial
- Quality of Life in Patients with Advanced Renal Cell Carcinoma Given Nivolumab Versus Everolimus in CheckMate 025: a Randomised, Open-label, Phase 3 Trial published by since 2016 with ISBNs. The book ISBN 13 Code is and ISBN 10 Code is
- Reading Mode in Text Status is false and Reading Mode in Image Status is false
- The book has " Pages" is Printed at BOOK under Category
- Rated by Raters and have average rate at ""
- eBook written in en
- Book Preview Address: http://books.google.com/books?id=dPTXvQEACAAJ&dq=Carcinoma&hl=&cd=321&source=gbs_api
Book Preview
The Button is not working? Try The Alternative links for "Quality of Life in Patients with Advanced Renal Cell Carcinoma Given Nivolumab Versus Everolimus in CheckMate 025: a Randomised, Open-label, Phase 3 Trial by: ":
- Server 2: SECURE LINK